AIMS/HYPOTHESIS: Orexin A (OXA) modulates body weight, food intake and energy expenditure. In vitro, OXA increases PPARγ (also known as PPARG) expression and inhibits lipolysis, suggesting direct regulation of lipid metabolism. Here, we characterise the metabolic effects and mechanisms of OXA action in adipocytes. METHODS: Isolated rat adipocytes and differentiated murine 3T3-L1 adipocytes were exposed to OXA in the presence or absence of phosphoinositide 3-kinase (PI3K) inhibitors. Pparγ expression was silenced using small interfering RNA. Glucose uptake, GLUT4 translocation, phosphatidylinositol (3,4,5)-trisphosphate production, lipogenesis, lipolysis, and adiponectin secretion were measured. Adiponectin plasma levels were determined in rats treated with OXA for 4 weeks. RESULTS: OXA PI3K-dependently stimulated active glucose uptake by translocating the glucose transporter GLUT4 from cytoplasm into the plasma membrane. OXA increased cellular triacylglycerol content via PI3K. Cellular triacylglycerol accumulation resulted from increased lipogenesis as well as from a decrease of lipolysis. Adiponectin levels in chow- and high-fat diet-fed rats treated chronically with OXA were increased. OXA stimulated adiponectin expression and secretion in adipocytes. Both pharmacological blockade of peroxisome proliferator-activated receptor γ (PPARγ) activity or silencing Pparγ expression prevented OXA from stimulating triacylglycerol accumulation and adiponectin production. CONCLUSIONS/ INTERPRETATION: Our study demonstrates that OXA stimulates glucose uptake in adipocytes and that the evolved energy is stored as lipids. OXA increases lipogenesis, inhibits lipolysis and stimulates the secretion of adiponectin. These effects are conferred via PI3K and PPARγ2. Overall, OXA's effects on lipids and adiponectin secretion resemble that of insulin sensitisers, suggesting a potential relevance of this peptide in metabolic disorders.
AIMS/HYPOTHESIS: Orexin A (OXA) modulates body weight, food intake and energy expenditure. In vitro, OXA increases PPARγ (also known as PPARG) expression and inhibits lipolysis, suggesting direct regulation of lipid metabolism. Here, we characterise the metabolic effects and mechanisms of OXA action in adipocytes. METHODS: Isolated rat adipocytes and differentiated murine 3T3-L1 adipocytes were exposed to OXA in the presence or absence of phosphoinositide 3-kinase (PI3K) inhibitors. Pparγ expression was silenced using small interfering RNA. Glucose uptake, GLUT4 translocation, phosphatidylinositol (3,4,5)-trisphosphate production, lipogenesis, lipolysis, and adiponectin secretion were measured. Adiponectin plasma levels were determined in rats treated with OXA for 4 weeks. RESULTS: OXA PI3K-dependently stimulated active glucose uptake by translocating the glucose transporter GLUT4 from cytoplasm into the plasma membrane. OXA increased cellular triacylglycerol content via PI3K. Cellular triacylglycerol accumulation resulted from increased lipogenesis as well as from a decrease of lipolysis. Adiponectin levels in chow- and high-fat diet-fed rats treated chronically with OXA were increased. OXA stimulated adiponectin expression and secretion in adipocytes. Both pharmacological blockade of peroxisome proliferator-activated receptor γ (PPARγ) activity or silencing Pparγ expression prevented OXA from stimulating triacylglycerol accumulation and adiponectin production. CONCLUSIONS/ INTERPRETATION: Our study demonstrates that OXA stimulates glucose uptake in adipocytes and that the evolved energy is stored as lipids. OXA increases lipogenesis, inhibits lipolysis and stimulates the secretion of adiponectin. These effects are conferred via PI3K and PPARγ2. Overall, OXA's effects on lipids and adiponectin secretion resemble that of insulin sensitisers, suggesting a potential relevance of this peptide in metabolic disorders.
Authors: J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai Journal: Neuron Date: 2001-05 Impact factor: 17.173
Authors: J Rieusset; F Andreelli; D Auboeuf; M Roques; P Vallier; J P Riou; J Auwerx; M Laville; H Vidal Journal: Diabetes Date: 1999-04 Impact factor: 9.461
Authors: Krzysztof W Nowak; Mathias Z Strowski; Malgorzata M Switonska; Przemyslaw Kaczmarek; Vandana Singh; Marzena Fabis; Pawel Mackowiak; Magdalena Nowak; Ludwik K Malendowicz Journal: Int J Mol Med Date: 2005-06 Impact factor: 4.101
Authors: K Zwirska-Korczala; M Adamczyk-Sowa; P Sowa; K Pilc; R Suchanek; K Pierzchala; G Namyslowski; M Misiolek; K Sodowski; I Kato; A Kuwahara; R Zabielski Journal: J Physiol Pharmacol Date: 2007-03 Impact factor: 3.011
Authors: H Tsuneki; S Murata; Y Anzawa; Y Soeda; E Tokai; T Wada; I Kimura; M Yanagisawa; T Sakurai; T Sasaoka Journal: Diabetologia Date: 2008-02-07 Impact factor: 10.122
Authors: Marcela Nouzova; Anne Brockhoff; Jaime G Mayoral; Marianne Goodwin; Wolfgang Meyerhof; Fernando G Noriega Journal: Peptides Date: 2011-08-03 Impact factor: 3.750
Authors: Ayman M Arafat; Przemysław Kaczmarek; Marek Skrzypski; Ewa Pruszyńska-Oszmałek; Paweł Kołodziejski; Aikaterini Adamidou; Stephan Ruhla; Dawid Szczepankiewicz; Maciej Sassek; Maria Billert; Bertram Wiedenmann; Andreas F H Pfeiffer; Krzysztof W Nowak; Mathias Z Strowski Journal: Diabetologia Date: 2014-07-27 Impact factor: 10.122
Authors: Tatiana Wojciechowicz; Marek Skrzypski; Dawid Szczepankiewicz; Iwona Hertig; Paweł A Kołodziejski; Maria Billert; Mathias Z Strowski; Krzysztof W Nowak Journal: Exp Biol Med (Maywood) Date: 2016-05-10
Authors: A M Arafat; P Kaczmarek; M Skrzypski; E Pruszyńska-Oszmalek; P Kołodziejski; D Szczepankiewicz; M Sassek; T Wojciechowicz; B Wiedenmann; A F H Pfeiffer; K W Nowak; M Z Strowski Journal: Diabetologia Date: 2012-12-22 Impact factor: 10.122